Farlong completes three year clinical trial on ginseng

Results of a three year study have shown a significant decrease in serum LDL-C in a supplemented group compared to a placebo group

Farlong Pharmaceutical, a vertically integrated, plant-based ingredient and supplement company, has announced the clinical trial results on the effect of Farlong NotoGinseng (Farlong Ginseng Plus Panax Notoginseng extract) on cholesterol and blood pressure.

A randomised, placebo-controlled, double-blind, parallel study on one hundred healthy adults was conducted December 2016 through June 2019. The findings demonstrated that Farlong NotoGinseng supplementation is well tolerated and has a positive influence on reducing the risk of cardiovascular disease by decreasing blood pressure and selectively increasing HDL-C.

Testing

Sponsored by Farlong Pharmaceutical and conducted by KGK Science, the primary objective was the difference in serum LDL-C from baseline to week 12 between Farlong NotoGinseng and placebo after 12 weeks of supplementation.

The secondary objectives were the difference in serum LDL-C, blood pressure, triglycerides, HDL-C, total cholesterol and in endothelial vasodilation as measured by the EndoPAT from baseline to week eight and week 12 between Farlong NotoGinseng and placebo.

Over a 12 week period, the participants were given one serving (two capsules) of the investigational product or placebo to take orally at the same time every day, 30 minutes before a meal for 84 days.

The placebo group had increases in systolic and diastolic blood pressures

The results showed a significant decrease in serum LDL-C in Farlong NotoGinseng group from baseline to week eight. LDL Cholesterol is sometimes called the “bad” cholesterol because a high LDL level leads to a buildup of cholesterol in people’s arteries. There was a slight increase in serum HDL-C following 12 weeks of supplementation with Farlong NotoGinseng. HDL (high-density lipoproteins) cholesterol is the “good” cholesterol. There were also within-group decreases in both systolic and diastolic blood pressures.

The placebo group had increases in systolic and diastolic blood pressures and a decrease in serum HDL-C. Clinicians suggest that if left unaddressed, these participants may progress to a disease state, and even a small reduction in blood pressure is clinically meaningful in populations at risk for developing cardiovascular diseases.

NotoGinseng

Farlong NotoGinseng is designed to help maintain normal health of the cardiovascular system. The capsule consists of highly concentrated pharmaceutical grade Ginseng Plus Panax Notoginseng extract, containing high potency notoginsenoside R1, ginsenoside Rb1, ginsenoside Rg1, which are the most active components along with other minor ginsenosides, such as ginsenoside Rd, Re, Rb2 and Rg3, ext. to nutritionally support healthy heart function, blood circulation, and performance.

Companies